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equations/algorithms from the UKPDS Outcomes Model (68) to predict the long 
term risks of type 2 diabetes-related complications. The impact of treatments 
on risk factors and side effects was based on clinical trials, observational stud-
ies, systematic reviews and meta-analyses of relevant RCTs, as well as the most 
recent findings on the potential benefit of DPP4 on other-cause mortality and 
cardiovascular diseases and the possible detrimental effect of sulfonylurea on 
myocardial infarction (MI). European patient profiles and Belgium-specific data 
on drug prices, diabetes-related complication treatment costs, treatment patterns 
and guidelines were used. Results: A sitagliptin-based treatment strategy was 
projected to cost € 1,102 more than a sulfonylurea-based treatment strategy per 
patient lifetime, with the majority of excess costs from prescription drugs. Life 
expectancy was 0.077 years greater per patient on a sitagliptin-based strategy 
compared to a sulfonylurea-based strategy. The discounted gain in QALY was 0.082 
years with the sitagliptin-based strategy, driven by better hypoglycemia, weight, 
and MI risk profile. The estimated ICER was € 13,460/QALY. Sensitivity analyses 
demonstrated that the ICER was somewhat sensitive to the price of sulfonylureas 
and the weight utility decrement, and most sensitive to assumptions on relative 
risk parameters. When no relative risk reduction on MI or other-cause mortality 
was assumed, the ICER was € 17,543/QALY and € 17,053/QALY, respectively. When 
no relative risk reduction on either MI or other-cause mortality was assumed, the 
ICER increased to € 23,691/QALY. ConClusions: Using a threshold of € 15,000 per 
QALY gained, compared to a sulfonylurea-based treatment strategy, a sitagliptin-
based treatment strategy was cost-effective in metformin-failed patients with 
type 2 diabetes in Belgium.
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objeCtives: Type 2 diabetes (T2D) patients on basal insulin with uncontrolled 
HbA1c levels often receive an add-on with bolus insulin to lower HbA1c levels. 
The aim of this analysis is to estimate long-term cost-effectiveness of treating 
T2D patients with – a recently introduced – twice daily (BID) exenatide add-on to 
basal insulin strategy from a Turkish health care perspective. Methods: Clinical 
inputs for both treatment strategies were taken from the GWDM clinical trial. The 
strategies were assessed using a micro-simulation disease model (CARDIFF). The 
model predicted micro-and macro-vascular complications based on the UKPDS 
equations. The incidence of adverse events, diabetes related complications and 
changes in body weight yielded estimates of health care costs and health utilities. 
The direct (T2D and complication) costs in the model reflect the Social Security 
Institution costs. Discounting both costs and effects at 3% over the 40 year follow-
up of the model, resulted in life time estimates of costs and quality-adjusted life 
years (QALYs) on both treatment strategies. Deterministic and probabilistic sensi-
tivity analyses, as well as elaborate scenario analyses were performed. Results: 
Results showed that exenatide treatment significantly improves QALYs by 0.60 (95% 
CI: 0.24 to 0.97). Health effects were reached at an additional cost of 217 $ (95% CI: 
-356$ to 976$), resulting in an incremental cost-effectiveness ratio of 362 $ per QALY 
gained. Scenario analyses showed that these results were robust to changes in 
input parameters. At a willingness-to-pay threshold of 30,000 $/QALY the exenatide 
strategy had a near 100% probability of being cost-effective compared to bolus insu-
lin. ConClusions: A twice daily exenatide add-on to basal insulin treatment for 
T2DM patients with uncontrolled HbA1c levels is considered a highly cost-effective 
strategy from the Turkish public health care perspective.
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objeCtives: When HbA1c is elevated above target in Type 2 diabetes (T2D) patients 
treated with basal insulin, the widespread strategy consists of adding mealtime 
insulin. An alternative option is adding twice-daily exenatide (BID), a glucagon-like 
peptide-1 receptor agonist. The objective was to estimate the cost-effectiveness in 
Spain of exenatide BID compared to mealtime bolus insulin lispro, both added to 
insulin glargine and metformin. Methods: The published and validated CARDIFF 
long-term diabetes model was used to estimate the direct medical costs and quality-
adjusted life years (QALYs) associated with each strategy. Patient characteristics at 
baseline, efficacy and safety inputs were all derived from a head-to-head, double-
blind, randomized controlled trial (NCT00960661), comparing both strategies for 
30 weeks. Based on the United Kingdom Prospective Diabetes Study-68 equations, 
the model predicted long-term disease progression and occurrence of micro- 
and macro-vascular complications, including mortality. Costs and utilities were 
assigned to complications, hypoglycaemias, adverse events and body mass index 
changes. The analyses were performed from the perspective of the Spanish health 
care payer, over a lifetime horizon, at a discount rate of 3% (costs and health out-
comes). Univariate and probabilistic sensitivity analyses were conducted. Results: 
Treatment with exenatide BID was projected to produce an incremental benefit of 
0.61 QALYs (95 % CI: 0.26 to 0.99) compared to treatment with insulin lispro, at an 
additional cost of € 146 (95% CI: -€ 1,114 to € 1,679) resulting in an incremental cost-
effectiveness ratio of € 239 per QALY gained. The exenatide BID strategy reached a 
probability near 100% of being cost-effective at a willingness-to-pay threshold of 
€ 2,500 per QALY gained. Sensitivity analyses showed that results were robust to vari-
ation in range of model parameters. ConClusions: Exenatide BID was predicted 
to be a cost-effective treatment alternative to mealtime bolus insulin in Spain for 
T2D patients not at target with insulin glargine.
each drug), as well as lab and imaging tests, were collected with the Delphi tech-
nique via an expert panel with 11 experienced endocrinologists, from University 
and Public Hospital specialized units. Local unit cost data were collected from 
officially published sources (Ministry of Health and Social Insurance Funds). One 
way sensitivity analyses were performed to test the results. Results: Lanreotide 
Autogel reduced total costs of acromegaly treatment by € 29,896 per patient over 
the 30-year time horizon. 93% of the savings were attributed to the reduction in 
drug acquisition and administration costs. Discount rate was the most influential 
parameter in the sensitivity analysis. The total cost of managing acromegaly in 
Greece, including lab and imaging tests, over a 5-year time horizon was estimated 
to range between € 22.9 and € 22.2 million, with a 30% and 60% market share for 
Lanreotide Autogel, respectively. Therefore, doubling Lanreotide Autogel’s share 
would lead to total savings of € 781,604. ConClusions: Lanreotide Autogel in 
comparison with Octreotide LAR may result in a reduction of the total cost in the 
management of acromegaly in Greece.
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objeCtives: To compare dipeptdyl-peptidase 4 inhibitors (DPP4i) and sulfonylurea 
(SU) for the treatment of type II diabetes mellitus in terms of economic impact and 
considering both the Italian National Health System (NHS) and the societal perspec-
tive. Methods: The economic evaluation was performed as a model-based cost-
minimization analysis for the comparison DPP4i and SU as second line therapy, in 
add-on to metformin, over 1-year period. Clinical events to be included in the model 
were selected from literature review and the opinion of a panel of clinical experts. 
Resources used were quantified and valued adopting costs and tariffs related to 
drugs used, glycaemic auto-monitoring, established control visits, incidence of 
hypoglicaemic events, macrovascular complications and the switch to insulin 
therapy. One-way sensitivity analyses for model inputs were conducted. Results: 
Due to the higher cost for drug acquisition in the base case analysis total direct costs 
for the Italian NHS were about 728 Euro per patient/year in the case of DPP4i and 
on average 702 Euro for SU. The overall yearly cost for the society was estimated to 
be about 728 Euro per patient in the case of DPP4i while it was on average 770 Euro 
when considering SU because DPP4i induced lower direct non-health costs related 
to stroke and an overall saving of 20.88 Euro per patient/year due to lower costs 
of productivity loss for hypoglicaemic events and stroke. ConClusions: The use 
of DPP4i was cost-saving from the societal perspective and just the high cost for drug 
acquistion made the adoption of DPP4i more costly than SU for the Italian NHS. This 
result outlined that DPP4i represents a valuable alternative for the management of 
diabetes both from a clinical and economic perspective and costs will be lowered 
overall just intervening on cost for drug acquisition.
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objeCtives: To evaluate the cost of using the dipeptidyl peptidase-4 inhibitor 
(DPP4i), saxagliptin, compared to sitagliptin and linagliptin, when used as triple 
therapy in combination with metformin and sulphonylurea (met+SU) for the 
treatment of patients with type 2 diabetes mellitus (T2DM) who are inadequately 
controlled on met+SU alone. Methods: Bucher adjusted indirect treatment com-
parisons (ITCs) were performed with regards to the key T2DM outcomes of HbA1c, 
weight and hypoglycaemia compared to sitagliptin and linagliptin. The ITCs found 
no statistically significant differences between saxagliptin compared to either sit-
agliptin or linagliptin in terms of effectiveness (as measured by Hb1Ac change from 
baseline), and saxagliptin was found to be at least as safe as the other therapies. 
Therefore, a cost-minimisation analysis over a 1-year time horizon was developed 
from a UK health care perspective. Drug costs were considered in the model, sourced 
from the British National Formulary (BNF; September 2013). The application of an 
annual discount rate of 3.5% and use of a longer time horizon (up to 5 years) were 
explored in a scenario analysis. Results: Saxagliptin was associated with a yearly 
cost of £410.80 per patient. The yearly cost per patient for sitagliptin was £432.38, 
and the yearly cost per patient for linagliptin was also £432.38, based on drug costs. 
Therefore, saxagliptin has similar costs compared to the other DPP4i’s. Applying the 
annual discount rate and using a longer time horizon, saxagliptin was associated 
with cost-savings of £97.43 per patient over 5 years compared to both sitagliptin 
and linagliptin. ConClusions: Saxagliptin as triple therapy in combination with 
met+SU was shown to be a cost-saving treatment option from a UK health care 
perspective for patients with T2DM who are inadequately controlled on met+SU 
alone. The cost-saving per patient over 5 years was modest, although this may be 
important in a large patient population.
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objeCtives: Assess the cost-effectiveness of sitagliptin versus sulfonylurea as 
an add-on therapy to metformin among type 2 diabetes patients currently on 
metformin but not achieving HbA1c goal in Belgium. Methods: We employed 
a previously published individual-level simulation model that incorporated risk 
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0.377 QALYs (95% CI: -0.227 to 0.754) and cost savings of € 264 (95% CI: -€ 1,879 to € 
2,768).. At a willingness-to-pay threshold of € 30,000 per QALY gained, SAXA strategy 
had an 82% probability to be cost-effective. Compared to TZD add-on to MET plus SU, 
the triple therapy with SAXA reached an incremental cost-effectiveness ratio of € 2,610 
per QALY gained. ConClusions: Saxagliptin was predicted to be a cost-effective 
option in Spain when a new drug needs to be added in T2DM patients inadequately 
controlled with metformin and sulphonylurea alone.
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objeCtives: To assess the cost-effectiveness of dapagliflozin, a sodium-glucose 
co-transporter-2 (SGLT-2) inhibitor versus dipeptidyl peptidase-4 inhibitor (DPP4i) 
both added on top of insulin, or compared to insulin alone (±oral anti-diabetes 
agents) for patients who are inadequately controlled on insulin strategy. Methods: 
The CARDIFF diabetes model was used. Clinical inputs were derived from a rand-
omized clinical trial comparing dapagliflozin add-on to insulin with insulin alone, 
and network-meta-analysis for the comparison with DPP4i. Together with United 
Kingdom Prospective Diabetes Study (UKPDS) equations, the model predicts disease 
progression and the number of micro- and macro-vascular complications, along 
with diabetes-specific and all-cause mortality. The perspective of the Spanish health 
care payer was adopted over a lifetime horizon. Costs and utilities were assigned 
to the appropriate model parameters to calculate total Quality-Adjusted-Life-Years 
(QALYs) and total costs. Deterministic and probabilistic sensitivity analyses were 
conducted. Results: Compared to insulin alone, dapagliflozin added to insulin was 
associated with 0.698 incremental QALYs (95%CI: 0.442; 1.211) at an additional cost 
of € 1,508 (95%CI: € 611; € 1,517), resulting in an incremental cost-effectiveness ratio 
(ICER) point estimate of € 2,159/QALY. Dapagliflozin was found to dominate DPP4i 
add-on to insulin, being associated with slightly less costs (-€ 51; 95%CI: -€ 913; € 553) 
and higher QALYs (0.168; 95%CI: -0.007; 0.417). At a willingness-to-pay threshold of 
€ 20,000/QALY, the dapagliflozin strategy was estimated to have a 100% probability 
of being cost-effective when compared to the insulin alone, and a 98% probability 
when compared to the DPP4i strategy. These findings were shown to be robust to 
variation in range of model parameters. ConClusions: Dapagliflozin added on 
top of Insulin was predicted to be a cost-effective (vs. insulin alone) and cost sav-
ing (vs DPP4i) alternative in Spain in combination with insulin for patients who are 
inadequately controlled with insulin treatment regimens.
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objeCtives: Tolvaptan is a selective vasopressin V2-receptor antagonist indicated 
for the treatment of adult patients with hyponatraemia (HN) secondary to syndrome 
of inappropriate antidiuretic hormone secretion (SIADH). To date there have been 
no published economic evaluations assessing the cost effectiveness of tolvaptan 
in this indication. The aim of this study was to evaluate the cost effectiveness 
of tolvaptan versus no active treatment (NAT) from a Swedish societal perspec-
tive. Methods: The economic evaluation considers a hypothetical population of 
individuals with HN secondary to SIADH who have either failed to respond to fluid 
restriction or for whom the use of fluid restriction is not suitable. The analysis con-
siders three clinically relevant patient populations within the SIADH indication: ‘all 
SIADH’, small-cell lung cancer (SCLC) and pneumonia. A discrete event simulation 
was developed to model the progression of individuals through multiple inpatient 
admissions over a 30 day time horizon (180 days in the SCLC scenario). Key sources 
of evidence included randomised controlled trials (SALT I & II) and observational 
data sources. Unit costs were collected from publicly available sources. Utility values 
were obtained from mapping the SF-12 scores from the SALT I & II trials to EQ-5D. 
The primary outcome of the analysis was the incremental cost-effectiveness ratio 
(ICER) expressed as a cost per quality-adjusted life-year (QALY). Results: In the 
‘all SIADH’ population tolvaptan was associated with reduced costs (SEK 5,778) and 
increased QALYs (0.0019) versus NAT and was therefore dominant. In the SCLC and 
pneumonia subgroups tolvaptan was also associated with reduced costs and QALY 
improvements. The results were most sensitive to the duration of tolvaptan treat-
ment and the assumptions around duration of hospitalisation. ConClusions: In 
all populations considered (all SIADH, SCLC and pneumonia) tolvaptan was domi-
nant compared to NAT being associated with reduced costs and increased QALYs.
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objeCtives: To assess the cost-effectiveness of the novel SGLT2is empagliflozin 10mg 
and 25mg compared to other SGLT2is (canagliflozin 100mg, canagliflozin 300mg, and 
dapagliflozin 10mg) when administered as an add-on to metformin for the treat-
ment of patients with T2DM in the UK. Methods: A micro-simulation model was 
developed, based on the United Kingdom Prospective Diabetes Study (UKPDS68) and 
the Januvia Diabetes Economic (JADE) model, to estimate long-term diabetes-related 
complications, QALYs and costs in a cohort of T2DM patients initiating dual therapy. 
The model was populated with the results of a network meta-analysis that estimated 
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objeCtives: To evaluate the economic burden among patients diagnosed with 
Cushing’s disease (CD) in the U.S. Medicaid program. Methods: Patients diagnosed 
with CD (International Classification of Disease, 9thRevision, Clinical Modification 
(ICD-9-CM) diagnosis code 255.0) were identified using U.S. Medicaid data from 01 
January 2008 through 31 December 2010. The initial diagnosis date was designated 
as the index date. A matching comparator cohort was created including patients of 
the same age, race and gender but without a CD diagnosis, and a randomly-chosen 
index date to minimize selection bias. Patients in both cohorts were required to be 
age ≥ 18 years, with continuous medical and pharmacy benefits for 1 year pre- and 
1 year post-index date. One-to-one propensity score matching (PSM) was used to 
compare health care costs and utilizations during the follow-up period between the 
diseased and comparison cohorts, and was adjusted for baseline demographic and 
clinical characteristics. Results: After risk adjustment by PSM, a total of 340 patients 
in each cohort were matched. CD patients had significantly higher health care utili-
zation, including inpatient admissions (36.18% vs. 12.53%, p< 0.0001) and long-term 
care (5.29% vs. 2.06%, p< 0.05), other service (100% vs. 94.12%, p< 0.0001) and pharmacy 
visits (84.41% vs. 78.24%, p< 0.05), compared to those without the disease. CD patients 
incurred significantly higher inpatient ($4,688 vs. $1,139, p< 0.05) and pharmacy costs 
($4,054 vs. $2,100, p< 0.001) compared to those without CD. Long-term care and other 
service costs incurred were higher for CD patients, compared to comparison patients, 
but were not statistically significant. ConClusions: In the current study, CD patients 
in the U.S. Medicaid program had a higher burden of illness in terms of health care 
resource utilization and costs, compared to those without a CD diagnosis.
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objeCtives: The Dose Adjustment For Normal Eating (DAFNE) structured education 
programme is shown to be effective both in terms of clinical outcomes and cost-
effectiveness outcomes in the treatment of T1DM. DAFNEPlus aims to revise the 
DAFNE 5-day curriculum based on psychological and sociological findings in DAFNE, 
input from DAFNE graduates and emerging knowledge around behavioural science 
and technological developments. The current suggested primary endpoint is for the 
DAFNEplus programme to have an additional 20% DAFNE participants (70% in total) 
achieve either, (a) a reduction of at least 0.5% in HbA1c, or (b) to have an HbA1c below 
7.5% (58.5 mmol/mol), at 12 months. This paper undertakes pre-trial what-if cost-
effectiveness analyses concerning the DAFNEPlus programme, which aim to be use-
ful both in the design of the intervention itself and of the proposed trial. Methods: 
The Sheffield Type 1 Diabetes Policy Model is an individual patient-level simulation 
model of T1DM. It includes long-term microvascular (retinopathy, neuropathy and 
nephropathy) and macrovascular (myocardial infarction, stroke, revascularization 
and angina) diabetes-related complications and acute adverse events (severe hypo-
glycaemia and diabetic ketoacidosis). Econometric methods were used to obtain 
the target level of HbA1c responders in the DAFNEPlus arm. Results: DAFNEplus 
would be considered as cost-effective if the additional spending on the intervention 
would be limited to £455-£751 per patient per year, depending on the assumptions 
on the length of maintenance period for the HbA1c benefit and the target HbA1c 
responder endpoint (70% in total) being achieved in the future trial. To achieve a 
more favourable cost-effectiveness probability of 80%, for example, the additional 
per patient per year cost should be restricted to £393-£574 range. ConClusions: 
Pre-trial modelling has enabled a clear understanding of the threshold range for the 
annual cost of DAFNEplus, which is still being designed, in order to be considered 
as cost-effective at the £20,000/QALY threshold.
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objeCtives: In patients with type 2 diabetes mellitus (T2DM), when blood glucose 
is not adequately controlled by the combination of metformin (MET) and sulphony-
lurea (SU), the clinician has to choose between adding a third oral drug or starting 
insulin therapy. The objective of this study was to assess the cost-effectiveness in the 
Spanish setting of adding saxagliptin (SAXA) to MET and SU, compared to adding basal 
insulin (INS). Additionally, the SAXA strategy was compared with a thiazolidinedione 
(TZD), also added on top of MET and SU. Methods: The published and validated 
CARDIFF long-term diabetes model was used to estimate the direct medical costs and 
quality-adjusted life years (QALYs) associated with each strategy. Clinical inputs were 
obtained from a network meta-analysis. Based on the United Kingdom Prospective 
Diabetes Study equations, the model predicted disease progression and occurrence 
of micro- and macro-vascular complications, including mortality. Costs and utilities 
were applied to complications, hypoglycaemias and body mass index changes. The 
perspective of the Spanish Healthcare System was adopted over a lifetime horizon, 
at a discount rate of 3% (costs and health outcomes). Univariate and probabilistic 
sensitivity analyses were conducted. Results: SAXA add-on to MET plus SU resulted 
in a dominant strategy compared to INS add-on to MET plus SU, providing a gain of 
